VIDEO: Use of precision medicine ‘encouraging’ in prostate cancer treatment
Click Here to Manage Email Alerts
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of new precision medicine therapies in prostate cancer, presented at ASCO Annual Meeting.
Chehrazi-Raffle, a medical oncologist at the City of Hope Duarte Cancer Center, examined the NEPTUNE study, which looked at nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) in metastatic castration-resistant prostate cancer, while touching on the state of precision medicine as a whole.
“In the last 4 years, we've seen guidelines adapt to incorporate germline and somatic testing in all patients with metastatic disease. And we're seeing rates of those sorts of tests increase as time goes on, which is really encouraging,” Chehrazi-Raffle said.
Collapse
Click Here to Manage Email Alerts